Sydney spinout lands $273m deal to develop drugs for psychiatric disorders

May 05, 2023

Photo: Stefanie ZingsheimKinoxis was established to commercialise discoveries of novel molecules with the potential to treat a range of psychiatric disorders. Associate Professor Bowen received the 2021 Prime Minister’s Prize for New Innovators in recognition of his scientific leadership at Kinoxis. He said: “I've spent nearly 15 years researching the oxytocin system as a potential target for developing new treatments. The oxytocin receptors in the brain have emerged as an attractive drug target but they have been intractable with small molecules. “More than 10 years ago my group began investigating the chemistry and pharmacology relating to the oxytocin receptor.

From left: Professor Michael Kassiou (School of Chemistry), Dr Hugh Marston (Boehringer), Associate Professor Michael Bowen (School of Psychology) and Hugh Alsop (Kinoxis) in the Chau Chak Wing Museum. Photo: Stefanie Zingsheim

Kinoxis was established to commercialise discoveries of novel molecules with the potential to treat a range of psychiatric disorders. Associate Professor Bowen received the 2021 Prime Minister’s Prize for New Innovators in recognition of his scientific leadership at Kinoxis.

He said: “I've spent nearly 15 years researching the oxytocin system as a potential target for developing new treatments. It’s truly special to be partnering with a leading global pharmaceutical company that shares our vision for its potential to transform the way we treat disorders of the brain and mind.

“This outcome demonstrates what can be achieved through industry-university partnerships. Co-founding Kinoxis and providing scientific leadership for the company and its partnership with the University has been the highlight of my career.”

The partnership will bring significant funding to the University to support further research in the School of Chemistry, School of Psychology, and the Brain and Mind Centre that will be conducted in close collaboration with experts from Boehringer Ingelheim and Kinoxis.

University of Sydney Vice-Chancellor and President, Professor Mark Scott, said: “This major partnership between University of Sydney spinout Kinoxis and Boehringer Ingelheim is a shining example of why the University is so committed to supporting research translation and commercialisation and the innovators who want to bring their ideas to life.”

Professor Kassiou said: “More than three million Australians suffer from illnesses that impair social functioning. The oxytocin receptors in the brain have emerged as an attractive drug target but they have been intractable with small molecules.

“More than 10 years ago my group began investigating the chemistry and pharmacology relating to the oxytocin receptor. We have discovered several series of small molecules, now licensed to Kinoxis, that have allowed us to target the oxytocin receptor in ways not previously possible.” 

“As lead inventor and co-founder of Kinoxis I am proud of what has been achieved.”

The source of this news is from University of Sydney

Popular in Research

China is using the world's largest online disinformation operation to harass Americans

Nov 15, 2023

Child sexual abuse survivors lend their voice to support others

Nov 15, 2023

Print on demand business with Printseekers.com

Sep 6, 2022

Cost of living pressures sees social cohesion hit record low

Nov 15, 2023

Professor Emeritus Walter Hollister, an expert in flight instrumentation and guidance, dies at 92

Nov 15, 2023

Cool Course: City as Text

Nov 15, 2023